UC CARES Reveals Impact of Ulcerative Colitis on European Patients at 10th Congress of the European Crohn’s and Colitis Organisation

UC CARES Reveals Impact of Ulcerative Colitis on European Patients at 10th Congress of the European Crohn’s and Colitis Organisation
shutterstock_181275317The pan-European Ulcerative Colitis Condition, Attitude, Resources and Educational Study (UC CARES) and Programme of Ulcerative Colitis Research Studies Utilising an Investigational Treatment (PURSUIT) presented their results on ulcerative colitis (UC) patients at the 10th Congress of the European Crohn’s and Colitis Organisation (ECCO) in Barcelona, Spain. The UC CARES study concluded that 91% of patients who received conventional therapies for moderate to severe UC across Europe perceived their UC as highly disturbing during a flare-up, while 40% of patients reported disruption even when they were in remission. “The UC CARES data remind us that regular flare-ups significantly disrupt quality of life. Most patients with UC want to get their disease under control without intermittent flares but many are still failing to achieve full disease control with conventional therapies. Understanding the impact of UC is important in the management of the disease, and clinicians need a focus on sustained symptom relief, ” says Paul Robison, Medical Director at MSD (Merck in the United States and Canada). Another important finding was the rate of very knowledgeable patients about their disease at 84%. Approximately 63% of p
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *